ActiTrexx GmbH | Finanzwire

Basculer en Français

10184	Companies
209559	Keywords
139675	Articles
111091	Press releases

Home
Companies
ActiTrexx GmbH

BRIEF

published on 10/20/2025 at 10:05, 5 months 20 days ago

ActiTrexx Completes Final Patient Treatment in GvHD Therapy Study

Clinical Study Graft-versus-Host Disease Actileucel Immune Therapy Regulatory T Cells
PRESS RELEASE

published on 10/20/2025 at 10:00, 5 months 20 days ago

ActiTrexx completes treatment of last patient with novel regulatory T cell therapy against Graft-versus-Host Disease
ActiTrexx completes treatment of last patient with novel regulatory T cell therapy against Graft-versus-Host Disease. Phase Ib/II study evaluates Actileucel for GvHD prevention

ActiTrexx Graft-versus-Host Disease Regulatory T Cell Therapy Actileucel Phase Ib/II Study
BRIEF

published on 03/19/2024 at 10:05, 2 years ago

ActiTrexx Initiates Treatment in Graft-versus-Host Disease Study with Novel T Cell Therapy

Clinical Study ActiTrexx Graft-versus-Host Disease Regulatory T Cell Therapy Actileucel
PRESS RELEASE

published on 03/19/2024 at 10:00, 2 years ago

ActiTrexx treats first patient with novel regulatory T cell therapy against Graft-versus-Host Disease
ActiTrexx GmbH treats first patient with novel regulatory T cell therapy for Graft-versus-Host Disease. Phase Ib/II study evaluates safety and feasibility of Actileucel treatment

Graft-versus-Host Disease Regulatory T Cell Therapy Actileucel ActiTrexx GmbH Phase Ib/II Study

Accesswire

Published on 04/09/2026 at 16:00, 2 hours 35 minutes ago

Banff Half Marathon Completes 2025 Emissions Assessment, Supporting Climate Action with Karbon-X
Published on 04/09/2026 at 14:40, 3 hours 55 minutes ago

Silver X Delivers Production Growth During the First Quarter of 2026
Published on 04/09/2026 at 14:00, 4 hours 35 minutes ago

Orogen Royalties Announces Mineral Reserve and Resource Update on Producing Ermitaño Royalty
Published on 04/09/2026 at 13:30, 5 hours 5 minutes ago

Datametrex Receives $6M Purchase Order for Data Centre from Fortune 500 Conglomerate
Published on 04/09/2026 at 13:30, 5 hours 5 minutes ago

ESGold Advances Toward Production and Exploration Drilling as Mill Buildout Progresses in Parallel

View all ACCESSWIRE

EQS Group

Published on 04/09/2026 at 18:15, 20 minutes ago

REPLY: Launch of a share buyback program for a maximum number of 3,607,950 shares
Published on 04/09/2026 at 15:59, 2 hours 36 minutes ago

Cairn Homes Plc: Holding(s) in Company
Published on 04/09/2026 at 15:57, 2 hours 38 minutes ago

Cairn Homes Plc: Holding(s) in Company
Published on 04/09/2026 at 15:40, 2 hours 55 minutes ago

Form 8.3 - The Vanguard Group, Inc.: LondonMetric Property plc
Published on 04/09/2026 at 15:39, 2 hours 55 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Schroders plc

Les Echos

Published on 04/09/2026 at 17:35, 1 hour ago

SUEZ - FY 2025
Published on 04/09/2026 at 15:57, 2 hours 37 minutes ago

Filing of CNP Assurances SA 2025 universal registration document and 2025 Solvency and Financial Condition Reports
Published on 04/09/2026 at 07:00, 11 hours 35 minutes ago

bioMérieux Unveils its BIOFIRE® SPOTFIRE® Molecular Testing Solution for the Pharmaceutical Industry, Redefining Rapid Mycoplasma Testing
Published on 04/08/2026 at 18:02, 1 day ago

Publication of the 2025 Universal Registration Document
Published on 04/08/2026 at 17:45, 1 day ago

DISCLOSURE OF SHARE CAPITAL AND VOTING RIGHTS

View all LES ECHOS COMFI WIRE